Proteomic Analysis of Inhibitor of Apoptosis Protein-like Protein-2 on MCF-7 Cell Growth

preprint OA: closed
View at publisher

Abstract

Backgrounds: Although inhibitor of apoptosis protein-like protein-2 (ILP-2) is regarded as a novel growth enhancer for breast cancer, its mechanism on breast cancer cell growth remains elusive. This study analysed the expression profiles of proteins with association to ILP-2 protein during Michigan Cancer Foundation-7 (MCF-7) breast cell growth for its mechanism on breast cancer cell growth. Methods: Isobaric tags for relative and absolute quantification analysis (iTRAQ) was applied on siRNA-5 and negative control groups of MCF-7 breast cancer cells to analyse protein expression profile correlated to ILP-2 during MCF-7 cell growth. Verification of iTRAQ data was by done by Western blot. Results: 4065 proteins were identified in the MCF-7 cells, with 241 of differentially expressed proteins (DEPs) (fold change ≥ 1.20 or ≤ 0.83 and P<0.05). A total of 156 upregulated and 85 downregulated proteins were found in the siRNA-5 group versus negative control group. These DEPs were associated with the extracellular matrix receptor interaction. Proteins from the top 10 biological processes were associated with signal transduction, regulation of cell proliferation, and immune system processes. The expression of AGA (N(4)-(beta-N-acetylglucosaminyl)-L- asparaginase), MT1E (metallothionein-1E) and TDO2 (tryptophan 2,3-dioxygenase) increased when the protein expression of ILP-2 was knocked-down. Conclusions: These results suggest that ILP-2 promotes MCF-7 cell growth by regulating cell proliferation, signal transduction, and immune system processes.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00